Showing results (41-50 of 452) with videos related to
Sort By:
Pageof 46
Medical Oncology (Northwood, London, England)|January 10, 2002
Treatment of the T98G glioblastoma cell line with antisense oligonucleotides directed toward mRNA encoding transforming growth factor-alpha and the epidermal growth factor receptorM Rubenstein, R Glick, T Lichtor, et al.Journal of Surgical Oncology|November 1, 1993
Renal cell carcinoma: the size variableW Frank, P Guinan, D Stuhldreher, et al.The Prostate|May 1, 1996
Suramin as adjuvant therapy with radical prostatectomyR Saffrin, P Chou, V Ray, et al.Methods and Findings in Experimental and Clinical Pharmacology|February 18, 1999
Paclitaxel is more effective than thalidomide in inhibiting LNCaP tumor growth in a prostate cancer modelP Guinan, M Shaw, Y Mirochnik, et al.Urology|December 1, 1989
BCG in management of transitional cell carcinoma invasive to prostateP Siami, S Chinn, M Clayton, et al.Journal of Surgical Oncology|February 11, 1998
An evaluation of the markers p53 and Ki-67 for their predictive value in prostate cancerI Uzoaru, M Rubenstein, Y Mirochnik, et al.Urological Research|January 1, 1991
GM-CSF restoration of a differentiated (growth factor-regulated) phenotype in an anaplastic tumorM Rubenstein, M Shaw, P Targonski, et al.Immunopharmacology and Immunotoxicology|January 1, 1990
Efficacy of immunopriming prior to isolation of tumor infiltrating lymphocytes for use in adoptive immunotherapyM Rubenstein, S Muchnik, M Chet, et al.Immunological Investigations|December 1, 1992
The effect of BCG on thoracic duct lymphocytesD Stuhldreher, W Frank, M Shaw, et al.The Prostate|January 1, 1989
Application of immunohistologic staining to develop a malignant index to aid in distinguishing benign from malignant prostatic tissueM Rubenstein, M W Shaw, V Ray, et al.Pageof 46